Jeil Pharma Holdings Inc (002620.KS)
KRW 7990.0
(-3.5%)
KRW 7990.0
(-3.5%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 201.82 Billion KRW | 11.82% |
| 2022 | 180.48 Billion KRW | -0.01% |
| 2021 | 180.5 Billion KRW | -5.61% |
| 2020 | 191.23 Billion KRW | 5.09% |
| 2019 | 181.97 Billion KRW | 222.33% |
| 2018 | 56.45 Billion KRW | 164.97% |
| 2017 | 21.3 Billion KRW | -84.23% |
| 2016 | 135.12 Billion KRW | -3.63% |
| 2015 | 140.21 Billion KRW | 8.8% |
| 2014 | 128.87 Billion KRW | 17.78% |
| 2013 | 109.41 Billion KRW | 1.52% |
| 2012 | 107.78 Billion KRW | -19.07% |
| 2011 | 133.17 Billion KRW | -0.57% |
| 2010 | 133.93 Billion KRW | 10.59% |
| 2009 | 121.11 Billion KRW | 27.05% |
| 2008 | 95.32 Billion KRW | -1.62% |
| 2007 | 96.89 Billion KRW | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 51.45 Billion KRW | 9.9% |
| 2024 Q1 | 46.81 Billion KRW | -9.88% |
| 2023 Q3 | 47.03 Billion KRW | -6.75% |
| 2023 Q2 | 50.43 Billion KRW | -18.73% |
| 2023 Q4 | 51.94 Billion KRW | 10.45% |
| 2023 FY | 201.82 Billion KRW | 11.82% |
| 2023 Q1 | 62.06 Billion KRW | 46.59% |
| 2022 Q3 | 44.56 Billion KRW | -8.17% |
| 2022 Q2 | 48.53 Billion KRW | 7.74% |
| 2022 Q1 | 45.04 Billion KRW | 10.32% |
| 2022 FY | 180.48 Billion KRW | -0.01% |
| 2022 Q4 | 42.33 Billion KRW | -5.0% |
| 2021 Q4 | 40.83 Billion KRW | -11.8% |
| 2021 Q1 | 45.32 Billion KRW | -7.09% |
| 2021 Q2 | 48.05 Billion KRW | 6.04% |
| 2021 Q3 | 46.29 Billion KRW | -3.66% |
| 2021 FY | 180.5 Billion KRW | -5.61% |
| 2020 Q4 | 48.78 Billion KRW | 4.51% |
| 2020 FY | 191.23 Billion KRW | 5.09% |
| 2020 Q1 | 47.9 Billion KRW | 4.23% |
| 2020 Q2 | 47.87 Billion KRW | -0.07% |
| 2020 Q3 | 46.67 Billion KRW | -2.5% |
| 2019 Q2 | 45.89 Billion KRW | 16.29% |
| 2019 Q1 | 39.46 Billion KRW | 21.54% |
| 2019 Q4 | 45.96 Billion KRW | -4.11% |
| 2019 Q3 | 47.93 Billion KRW | 4.44% |
| 2019 FY | 181.97 Billion KRW | 222.33% |
| 2018 FY | 56.45 Billion KRW | 164.97% |
| 2018 Q4 | 32.46 Billion KRW | 295.03% |
| 2018 Q3 | 8.21 Billion KRW | -0.3% |
| 2018 Q2 | 8.24 Billion KRW | -7.41% |
| 2018 Q1 | 8.9 Billion KRW | -7.73% |
| 2017 Q2 | 3.37 Billion KRW | -89.89% |
| 2017 FY | 21.3 Billion KRW | -84.23% |
| 2017 Q1 | 33.41 Billion KRW | -73.15% |
| 2017 Q3 | 4.22 Billion KRW | 25.2% |
| 2017 Q4 | 9.64 Billion KRW | 128.18% |
| 2016 Q1 | 33.78 Billion KRW | 0.0% |
| 2016 Q3 | 3.88 Billion KRW | 17.96% |
| 2016 Q4 | 124.45 Billion KRW | 3105.2% |
| 2016 Q2 | 3.29 Billion KRW | -90.26% |
| 2016 FY | 135.12 Billion KRW | -3.63% |
| 2015 FY | 140.21 Billion KRW | 8.8% |
| 2015 Q4 | - KRW | -100.0% |
| 2015 Q3 | 34.92 Billion KRW | 0.49% |
| 2015 Q2 | 34.75 Billion KRW | 5.48% |
| 2015 Q1 | 32.95 Billion KRW | -4.97% |
| 2014 Q2 | 34.34 Billion KRW | 14.34% |
| 2014 Q1 | 30.03 Billion KRW | 10.16% |
| 2014 FY | 128.87 Billion KRW | 17.78% |
| 2014 Q4 | 34.67 Billion KRW | 16.27% |
| 2014 Q3 | 29.82 Billion KRW | -13.16% |
| 2013 Q3 | 26.82 Billion KRW | -5.62% |
| 2013 Q4 | 27.26 Billion KRW | 1.66% |
| 2013 FY | 109.41 Billion KRW | 1.52% |
| 2013 Q1 | 26.91 Billion KRW | 11.46% |
| 2013 Q2 | 28.41 Billion KRW | 5.6% |
| 2012 Q4 | 24.14 Billion KRW | -13.46% |
| 2012 FY | 107.78 Billion KRW | -19.07% |
| 2012 Q1 | 28.31 Billion KRW | -0.85% |
| 2012 Q2 | 27.41 Billion KRW | -3.16% |
| 2012 Q3 | 27.9 Billion KRW | 1.75% |
| 2011 FY | 133.17 Billion KRW | -0.57% |
| 2011 Q4 | 28.55 Billion KRW | -27.35% |
| 2011 Q3 | 39.31 Billion KRW | 43.75% |
| 2011 Q2 | 27.34 Billion KRW | -20.2% |
| 2011 Q1 | 34.26 Billion KRW | 8.81% |
| 2010 Q2 | 36.33 Billion KRW | 17.55% |
| 2010 FY | 133.93 Billion KRW | 10.59% |
| 2010 Q4 | 31.49 Billion KRW | -10.53% |
| 2010 Q3 | 35.2 Billion KRW | -3.11% |
| 2010 Q1 | 30.9 Billion KRW | 5.04% |
| 2009 Q1 | 26.64 Billion KRW | 11.05% |
| 2009 Q2 | 31.5 Billion KRW | 18.24% |
| 2009 Q3 | 32.15 Billion KRW | 2.09% |
| 2009 Q4 | 29.42 Billion KRW | -8.5% |
| 2009 FY | 121.11 Billion KRW | 27.05% |
| 2008 Q3 | 24.49 Billion KRW | 2.98% |
| 2008 Q2 | 23.78 Billion KRW | 3.69% |
| 2008 Q1 | 22.93 Billion KRW | -9.07% |
| 2008 Q4 | 23.98 Billion KRW | -2.05% |
| 2008 FY | 95.32 Billion KRW | -1.62% |
| 2007 Q1 | 22.91 Billion KRW | 0.0% |
| 2007 Q4 | 25.22 Billion KRW | 8.22% |
| 2007 Q3 | 23.3 Billion KRW | -8.41% |
| 2007 Q2 | 25.44 Billion KRW | 11.05% |
| 2007 FY | 96.89 Billion KRW | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -333.978% |
| Dong-A Socio Holdings Co., Ltd. | 364.1 Billion KRW | 44.571% |
| Ildong Holdings Co., Ltd. | 198.88 Billion KRW | -1.476% |
| HANDOK Inc. | 151.36 Billion KRW | -33.333% |
| Kukje Pharma Co., Ltd. | 67.22 Billion KRW | -200.22% |
| Yuhan Corporation | 564.5 Billion KRW | 64.248% |
| Dong-A ST Co., Ltd. | 322.21 Billion KRW | 37.364% |
| SAMSUNG PHARM. Co., LTD. | 23.74 Billion KRW | -749.881% |
| Hanmi Pharm. Co., Ltd. | 835.85 Billion KRW | 75.854% |
| Hanall Biopharma Co.,Ltd | 75.03 Billion KRW | -168.954% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -1.437% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.64 Billion KRW | -396.491% |
| MYUNGMOON Pharm co.,Ltd | 94.51 Billion KRW | -113.533% |
| Hana Pharm Co., Ltd. | 140.85 Billion KRW | -43.283% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -333.978% |
| Ilsung Pharmaceuticals Co., Ltd. | 34.71 Billion KRW | -481.354% |
| REYON Pharmaceutical Co., Ltd. | 76.81 Billion KRW | -162.726% |
| Aprogen pharmaceuticals,Inc. | -12.04 Billion KRW | 1775.48% |
| JW Holdings Corporation | 446.15 Billion KRW | 54.764% |
| Ildong Pharmaceutical Co., Ltd. | 207.53 Billion KRW | 2.755% |
| Chong Kun Dang Pharmaceutical Corp. | 655.34 Billion KRW | 69.204% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 39.875% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -156.706% |
| Hyundai Pharmaceutical Co., Ltd. | 75.23 Billion KRW | -168.244% |
| Samil Pharmaceutical Co.,Ltd | 72.21 Billion KRW | -179.487% |
| Jeil Pharmaceutical Co.,Ltd | 183.81 Billion KRW | -9.796% |
| Yuyu Pharma, Inc. | 46.5 Billion KRW | -333.978% |
| Kwang Dong Pharmaceutical Co., Ltd. | 295.11 Billion KRW | 31.613% |
| Daewoong pharmaceutical Co.,Ltd | 681.55 Billion KRW | 70.388% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 39.875% |
| Yuhan Corporation | 564.5 Billion KRW | 64.248% |
| Yungjin Pharm. Co., Ltd. | 70.93 Billion KRW | -184.5% |
| Suheung Co., Ltd. | 99.02 Billion KRW | -103.805% |
| JW Pharmaceutical Corporation | 335.67 Billion KRW | 39.875% |
| Samjin Pharmaceuticals Co., Ltd. | 145.89 Billion KRW | -38.337% |
| Korea United Pharm Inc. | 173.48 Billion KRW | -16.332% |
| CKD Bio Corp. | 5.01 Billion KRW | -3928.136% |
| Daewon Pharmaceutical Co., Ltd. | 254.23 Billion KRW | 20.615% |
| Dongwha Pharm.Co.,Ltd | 184.12 Billion KRW | -9.612% |
| Whan In Pharm Co.,Ltd. | 98.12 Billion KRW | -105.677% |
| Shin Poong Pharm.Co.,Ltd. | 78.61 Billion KRW | -156.706% |
| Chong Kun Dang Holdings Corp. | 371.49 Billion KRW | 45.673% |
| Boryung Corporation | 333.26 Billion KRW | 39.442% |
| Bukwang Pharmaceutical Co., Ltd. | 50.04 Billion KRW | -303.276% |
| Ilyang Pharmaceutical Co.,Ltd | 198.96 Billion KRW | -1.437% |
| JW Lifescience Corporation | 51.32 Billion KRW | -293.223% |